Currently, there are 84.63M common shares owned by the public and among those 69.35M shares have been available to trade.
The company’s stock has a 5-day price change of 18.07% and 37.57% over the past three months. VRNA shares are trading 57.66% year to date (YTD), with the 12-month market performance up to 378.22% higher. It has a 12-month low price of $11.39 and touched a high of $70.40 over the same period. VRNA has an average intraday trading volume of 1.40 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 22.02%, 16.02%, and 69.66% respectively.
Institutional ownership of Verona Pharma Plc ADR (NASDAQ: VRNA) shares accounts for 75.49% of the company’s 84.63M shares outstanding.
It has a market capitalization of $5.79B and a beta (3y monthly) value of 0.21. The earnings-per-share (ttm) stands at -$2.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.73% over the week and 7.52% over the month.
Earnings per share for the fiscal year are expected to increase by 161.11%, and 305.39% over the next financial year.
Looking at the support for the VRNA, a number of firms have released research notes about the stock. TD Cowen stated their Buy rating for the stock in a research note on April 28, 2025, with the firm’s price target at $100. Cantor Fitzgerald coverage for the Verona Pharma Plc ADR (VRNA) stock in a research note released on April 21, 2025 offered a Overweight rating with a price target of $80. ROTH MKM was of a view on January 10, 2025 that the stock is Buy, while Wells Fargo gave the stock Overweight rating on October 03, 2024, issuing a price target of $50. Jefferies on their part issued Buy rating on May 22, 2023.
